

CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office : - Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • Fax No.: (022) 22074294 • CIN No.: L99999MH1942PLC003556 • PAN NO.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2021

Sr. No.	Particulars	(Rupees in Thousand)			
		Quarter Ended			Year Ended
		30th June 2021	31st March 2021	30th June 2020	31st March 2021
		Unaudited	Unaudited	Unaudited	Audited
I	Revenue from Operations				
II	Other Income				-
III	Total Revenue (I + II)	1,092	2,574	1,563	6,680
IV	Expenses	1,092	2,574	1,563	6,680
	(1) Cost Materials consumed	-	-	-	-
	(2) Purchase of Stock-in-Trade	-	-	-	-
	(3) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	-	-	-	-
	(4) Employee Benefits Expenses	352	367	245	1,262
	(5) Depreciation and Amortisation Expenses	-	239	-	239
	(6) Administrative and Other Expenses	429	1,194	431	2,071
	(7) Finance Costs	-	-	-	-
	Total Expenses	781	1,800	676	3,572
V	Profit/(Loss) before Exceptional and Extra ordinary Items and tax (III - IV)	311	774	887	3,108
VI	Exceptional Items	-	-	-	-
VII	Net Profit/(Loss) before Extra ordinary Items and Tax (V - VI)	311	774	887	3,108
VIII	Extra Ordinary Items	-	-	-	-
IX	Profit/(Loss) before Tax (VII-VIII)	311	774	887	3,108
X	Tax Expenses				
	(1) Current Tax	-	503	-	503
	(2) Tax Adjustment Previous Year	-	104	56	104
	(3) Deffered Tax	-	-	-	-
XI	Profit/(Loss) for the period from continuing operations (IX - X)	311	167	831	2,501
XII	Profit/(Loss) from discontinuing operations	-	-	-	-
XIII	Tax Expenses of discontinuing operations	-	-	-	-
XIV	Profit/(Loss) from discontinuing operations (after tax) (XII - XIII)	-	-	-	-
XV	Profit/(Loss) for the period (XI - XIV)	311	167	831	2,501
XVI	Other Comprehensive Income				
	A (i) Items that will not be reclassified to profit or loss				
	(ii) Income tax relating to items that will not be reclassified to profit or loss				
	B (i) Items that will not be reclassified to profit or loss				
	(ii) Income tax relating to items that will not be reclassified	-	-	-	-
XVII	Total Comprehensive Income for the period (XV+XVI) (Comprising Profit (Loss) and Other Comprehensive Income for the period)	311	167	831	2,501
XVIII	Earnings per Share :				
	(1) Basic	0.21	0.11	0.55	1.67
	(2) Diluted				

Notes :

- This Statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standard) Rules, 2015 and Companies (Indian Accounting Standard) Accounting Rules, 2016.
- The above Standalone Unaudited Financial Results for the Quarter Ended 30.06.2021 have been reviewed by the Audit Committee in their Meeting held on 26.07.2021 and approved by the Board of Directors of its Meeting held on 26.07.2021. The Limited Review Report of Auditors M/s VMD & Co. was also taken on record by the Board in its Meeting.
- The Company is not having any Subsidiary Company.
- The Company is having only one Segment and no other reportable segment in terms of Ind AS 108 in 'Operating Segment'.



For Chemo - Pharma Laboratories Limited

Ashok Somani
Ashok Somani

Director
DIN : 03063364

Place : Mumbai
Date : 26th July, 2021

CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office : - Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • Fax No.: (022) 22074294 • CIN No.: L99999MH1942PLC003556 • PAN NO.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

RECONCILIATION OF STANDALONE NET PROFIT FOR THE QUARTER ENDED 30TH JUNE, 2021

(Rs. in Thousand)

PARTICULARS	STANDALONE		
	UNAUDITED QUARTER ENDED 30.06.2021	UNAUDITED QUARTER ENDED 30.06.2020	AUDITED YEAR ENDED 31.03.2021
Reconciliation of Profit After Tax as reported earlier:			
Net Profit / (Loss) for the Period (as per AS)	311	831	2,501
Benefit / (Charge):			
Impact of Deferred Income (Government Grant) Amortized to Income	-	-	-
Impact of Fair Valuation of Financial Instruments	-	-	-
Impact of Actuarial Gain / Loss Taken OCI	-	-	-
Impact of Adjustment of Deferred Tax	-	-	-
Net Profit / (Loss) for the Period (as per AS)	311	831	2,501

For Chemo Pharma Laboratories Ltd.



Ashok Somani

Ashok Somani

Director

DIN : 03063364

Mumbai, 26th July, 2021